CL2021000892A1 - Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica - Google Patents

Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica

Info

Publication number
CL2021000892A1
CL2021000892A1 CL2021000892A CL2021000892A CL2021000892A1 CL 2021000892 A1 CL2021000892 A1 CL 2021000892A1 CL 2021000892 A CL2021000892 A CL 2021000892A CL 2021000892 A CL2021000892 A CL 2021000892A CL 2021000892 A1 CL2021000892 A1 CL 2021000892A1
Authority
CL
Chile
Prior art keywords
avexitide
treatment
hyperinsulinemic
hypoglycaemia
hyperinsulinemic hypoglycaemia
Prior art date
Application number
CL2021000892A
Other languages
English (en)
Spanish (es)
Inventor
Colleen M Craig
Lisa Porter
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of CL2021000892A1 publication Critical patent/CL2021000892A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2021000892A 2018-10-15 2021-04-12 Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica CL2021000892A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745915P 2018-10-15 2018-10-15
US201862746229P 2018-10-16 2018-10-16
US201962823493P 2019-03-25 2019-03-25

Publications (1)

Publication Number Publication Date
CL2021000892A1 true CL2021000892A1 (es) 2021-11-12

Family

ID=70283142

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000892A CL2021000892A1 (es) 2018-10-15 2021-04-12 Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica

Country Status (10)

Country Link
US (1) US20210338780A1 (https=)
EP (2) EP4233842A3 (https=)
JP (2) JP2022513351A (https=)
CN (1) CN112867730A (https=)
AU (2) AU2019359807B2 (https=)
BR (1) BR112021006968A2 (https=)
CA (1) CA3115527A1 (https=)
CL (1) CL2021000892A1 (https=)
IL (2) IL314504A (https=)
WO (1) WO2020081534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271753A1 (en) 2021-06-21 2022-12-29 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
CN121219002A (zh) * 2023-04-21 2025-12-26 小利兰斯坦福大学董事会 Glp-1r拮抗作用改善胃肠外科手术后的营养

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US20160185837A1 (en) * 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
LT3297653T (lt) * 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10653753B2 (en) * 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt) * 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai

Also Published As

Publication number Publication date
WO2020081534A1 (en) 2020-04-23
BR112021006968A2 (pt) 2021-07-27
IL282059A (en) 2021-05-31
AU2019359807A1 (en) 2021-05-13
US20210338780A1 (en) 2021-11-04
EP3867266A1 (en) 2021-08-25
AU2025208421A1 (en) 2025-08-14
CA3115527A1 (en) 2020-04-23
JP2025000798A (ja) 2025-01-07
IL314504A (en) 2024-09-01
JP2022513351A (ja) 2022-02-07
EP3867266A4 (en) 2022-07-13
AU2019359807B2 (en) 2025-04-24
EP4233842A2 (en) 2023-08-30
EP4233842A3 (en) 2023-10-25
CN112867730A (zh) 2021-05-28

Similar Documents

Publication Publication Date Title
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
EA201790398A1 (ru) Способы лечения заболевания печени
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CL2025002456A1 (es) Agonistas heterocíclicos de glp-1
AR105712A1 (es) Composiciones de insulina de rápida acción
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
CL2021001246A1 (es) Moduladores de expresión irf5.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp